Fig. 1 · Structure

Documents & Downloads

GW 4869

Cat. No. A11974 CAS 6823-69-4

N-SMase inhibitor

GW4869 is a cell permeable, selective inhibitor of N-SMase (neutral sphingomyelinase).

In Stock

Publications for GW 4869

3 publications citing this product

  1. Laozhi Xie, .et al. , ACS Nano, 2026, Jun 23;20(24):17442-17462 PMID: 42249854
  2. Salar Ghaffari Gabaran, .et al. , Biochem Pharmacol, 2025, Sep:239:117019 PMID: 40499840
  3. Guohao Wang, .et al. , Nat Commun, 2021, Sep 30;12(1):5733 PMID: 34593794

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Bioactivity / Mechanism

GW4869 inhibited full-length human nSMase2 with an approximate IC50 of 1 μM in a biochemical assay. Sensitivity depended on enzyme architecture: JX-CAT showed an approximate IC50 of 30 μM, whereas the isolated catalytic domain and D430A constructs were insensitive. These experiments support involvement of the juxtamembrane region and DK switch in inhibition; they do not locate a directly measured inhibitor-binding site. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

GW 4869 Research Summary

This section summarizes 3 in vitro studies and 1 in vivo study of GW 4869 from 4 published references. In vitro models include human nSMase2 full-length WT/D430A and purified CAT/JX-CAT constructs; B16F10 mouse melanoma cells. In vivo models include male C57BL/6J mice, 4 months old.

GW 4869 In Vitro Studies

At 5 µM for 16 hours, GW4869 reduced P100 extracellular-vesicle particles but increased P14 particles from SKBR3 and mouse L-cells. SKBR3 viability was maintained. These sedimentation-defined fractions overlap in size, so the findings support redistribution of vesicle release rather than uniform suppression of all extracellular vesicles. [2]

In B16F10 cells, free GW4869 had a weaker effect than the iron-containing HGF nanoformulation on CD63 and PD-L1 signals in a recovered exosome fraction. The evidence is a qualitative immunoblot comparison, not a particle-count inhibition measurement. HGF combines GW4869 with an iron-containing carrier, so its effects cannot be assigned to free GW4869 alone. [3]

Construct-dependent inhibition of human nSMase2

Biochemical assay · Human nSMase2 full-length WT/D430A and purified CAT/JX-CAT constructs [1]

GW4869 inhibited WT full-length enzyme and JX-CAT, whereas CAT and the residual activity of D430A constructs were insensitive. The pNPPC control was also insensitive.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Full-length WT nSMase2 sphingomyelin hydrolysisIC50 ∼1 μM[1]
Purified JX-CAT sphingomyelin hydrolysisIC50 ∼30 μM[1]
CAT/JX-CAT pNPPC hydrolysisQualitative control No inhibition at concentrations up to 100 μM[1]

Literature-Reported Treatment Conditions

Treatment concentration
Concentration-response assays; 100 μM in the pNPPC control
Method
Radiolabeled sphingomyelin hydrolysis in Triton X-100 mixed micelles; parallel pNPPC hydrolysis control
Reported limits
Exact incubation time for each figure and GW4869 supplier, counterion, hydration and lot are not specified in the read methods. General methods distinguish cell-lysate from purified-protein incubation ranges; those ranges are not assigned as exact figure-specific times.
Methods and source locations

Compound reported in the paper: GW4869; Compound label in the paper: GW4869

Evidence concerns the named GW4869 material used by the authors. Counterion/hydration and equivalence to the current Adooq lot are not established; no mass-to-molar conversion is made.

Figs. 5E and 6A–D; Results: GW4869 Inhibition and the DK Switch; Methods: SMase Activity and Analysis of Catalytic Activity Using pNPPC

Full-length WT nSMase2 sphingomyelin hydrolysis: Concentration-response enzyme assay; D430A residual activity was not inhibited — Fig. 6D; GW4869 Inhibition and the DK Switch

Purified JX-CAT sphingomyelin hydrolysis: Construct comparison; CAT and JX-CAT D430A were not inhibited — Fig. 6C; GW4869 Inhibition and the DK Switch

CAT/JX-CAT pNPPC hydrolysis: Alternative soluble substrate; 100 μM GW4869 shown in Fig. 5E — Fig. 5E and caption; GW4869 Inhibition and the DK Switch

Opposite effects on operational EV fractions

Cell-based study · Human SKBR3 breast cancer cells; murine L-cells in Fig. 1b–c [2]

GW4869 reduced P100 particle concentrations but increased P14 particles. SKBR3 viability was maintained. Fractions overlap in size and cannot establish vesicle origin solely from sedimentation.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
P100 and P14 EV particle concentrationsQualitative direction P100 decreased; P14 increased versus DMSO[2]
SKBR3 cell viabilityQualitative control No loss of viability reported[2]

Literature-Reported Treatment Conditions

Treatment concentration
5 µM
Exposure duration
16 hours (Fig. 1)
Method
Treatment in EV-free DMEM; differential EV fractionation followed by NTA and flow cytometry
Vehicle
DMSO control
Reported limits
Exact DMSO fraction, lot and counterion/hydration are not specified in the selected methods. Viability assay chemistry is not specified in the read scope.
Methods and source locations

Compound reported in the paper: GW4869; Compound label in the paper: GW4869

Evidence concerns the named GW4869 material used by the authors. Counterion/hydration and equivalence to the current Adooq lot are not established; no mass-to-molar conversion is made.

Fig. 1a–h; Fig. 2a–e; Results: GW4869 inhibition of nSMases differentially affects EV populations; Methods: Cell culture, Purification of MVs and Exos, Nanosight measurements, Flow cytometry

P100 and P14 EV particle concentrations: NTA; P14 increase additionally assessed by flow cytometry; normalized to cell number — Fig. 1b–g and caption; Fig. 2d–e

SKBR3 cell viability: Viability readout accompanying EV measurements; assay chemistry not specified in read scope — Fig. 1h; first Results subsection

Free GW4869 versus HGF in a recovered exosome fraction

Cell-based study · B16F10 mouse melanoma cells [3]

The recovered fraction showed a weaker effect with free GW4869 than with HGF on CD63 and PD-L1 immunoblot signals. HGF contains both GW4869 and iron in a hyaluronic-acid carrier; its response cannot be assigned to free drug alone.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
CD63 and PD-L1 signals in recovered conditioned-medium fractionQualitative comparison Free GW4869 had a weaker effect than HGF; free-drug signals remained visible[3]

Literature-Reported Treatment Conditions

Treatment concentration
20 μM GW4869 in main-text exosome-isolation/Western-blot methods; SI Fig. 8 compares 0, 6.25, 12.5, 25 and 50 μM
Method
Recovered conditioned-medium fraction analyzed for CD63 and PD-L1 by Western blot; GAPDH used as loading control
Vehicle
PBS comparator; free-drug solvent not specified for Fig. 3a
Co-treatment
Free GW4869 compared with PBS, HACA-Fe and HGF (GW4869 plus iron-containing carrier)
Reported limits
Fig. 3a exposure duration and free-drug solvent are not specified in its direct isolation/blot methods. The adjacent 24-hour T-cell/exosome experiment is a distinct design and is not used to fill this gap. Salt, lot and catalog number are not specified.
Methods and source locations

Compound reported in the paper: GW4869; Compound label in the paper: GW4869

Evidence concerns the named GW4869 material used by the authors. Counterion/hydration and equivalence to the current Adooq lot are not established; no mass-to-molar conversion is made.

Fig. 3a; Supplementary Fig. 8 (SI physical page 5); Methods: Materials, Exosome isolation, Western blot analysis

CD63 and PD-L1 signals in recovered conditioned-medium fraction: Western blot; GAPDH loading control; representative of three experiments — Fig. 3a; Supplementary Fig. 8, SI physical page 5

GW 4869 In Vivo Studies

In male C57BL/6J mice, GW4869 at 1.25 mg/kg intraperitoneally once daily for 21 days reduced cortical neutral sphingomyelinase activity by a reported 64.3%, while acid sphingomyelinase activity was unchanged. This tissue-assay result does not establish a brain drug concentration or efficacy across disease models. [4]

Cortical neutral versus acid sphingomyelinase activity

Animal study · Male C57BL/6J mice, 4 months old [4]

Systemic GW4869 reduced cortical neutral sphingomyelinase activity, while acid activity was unchanged relative to vehicle. This measures tissue enzyme activity rather than pharmacokinetics or universal in-vivo efficacy.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Cortical neutral and acid sphingomyelinase activityReported relative reduction Neutral activity decreased by 64.3%; acid activity unchanged[4]

Conditions shared by the study groups

Route
Intraperitoneal
Frequency
Once daily
Treatment course
21 daily injections; initiated 7 days before and continued during behavioral testing
Vehicle
Saline with 2.5% dimethylsulfoxide
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Systemic GW4869
1.25 mg/kg
Vehicle-injected mice (2.5% dimethylsulfoxide vehicle)Cortical neutral sphingomyelinase activity decreased by 64.3%; acid sphingomyelinase activity was unchanged.[4]
Systemic GW4869
Model: Male C57BL/6J mice, 4 months old
Reported limits: Exact salt/hydration, catalog number, lot and direct brain drug concentration are not established.
Methods and source locations

Compound reported in the paper: GW4869; Compound label in the paper: GW4869

Evidence concerns the named GW4869 material used by the authors. Counterion/hydration and equivalence to the current Adooq lot are not established; no mass-to-molar conversion is made.

Fig. 1A–B and caption; first Results subsection; Experimental Procedures: Animals and Sphingomyelinase activity assay

Cortical neutral and acid sphingomyelinase activity: Amplex Red sphingomyelinase assay at neutral versus acidic pH; cortex; n = 12 treated and 13 vehicle; mean ± S.D. in Fig. 1 — Fig. 1A–B and caption; first Results paragraph

Systemic GW4869 · Experimental Procedures: Animals; Fig. 1A–B; first Results subsection

Specifications

Manufacturer Adooq Bioscience
Actions Inhibitor
CAS Number 6823-69-4
Applications N-SMase inhibitor
Formula C30H28N6O2.2HCl
Molecular Weight 577.5
SMILES
O=C(NC1=CC=C(C2=NCCN2)C=C1)/C=C/C3=CC=C(/C=C/C(NC4=CC=C(C5=NCCN5)C=C4)=O)C=C3.[H]Cl.[H]Cl

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO Insoluble
Water Insoluble
Ethanol Insoluble

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

GW 4869 Research References

  1. [1] Airola MV, Shanbhogue P, Shamseddine AA, et al. Structure of human nSMase2 reveals an interdomain allosteric activation mechanism for ceramide generation Proceedings of the National Academy of Sciences of the United States of America (2017). PMID: 28652336 DOI: 10.1073/pnas.1705134114 Source material
  2. [2] Menck K, Sönmezer C, Worst TS, et al. Neutral sphingomyelinases control extracellular vesicles budding from the plasma membrane Journal of extracellular vesicles (2017). PMID: 29184623 DOI: 10.1080/20013078.2017.1378056 Source material
  3. [3] Wang G, Xie L, Li B, et al. A nanounit strategy reverses immune suppression of exosomal PD-L1 and is associated with enhanced ferroptosis Nature communications (2021). PMID: 34593794 DOI: 10.1038/s41467-021-25990-w Source material
  4. [4] Tabatadze N, Savonenko A, Song H, et al. Inhibition of neutral sphingomyelinase-2 perturbs brain sphingolipid balance and spatial memory in mice Journal of neuroscience research (2010). PMID: 20629193 DOI: 10.1002/jnr.22438 Source material

Publications

3 publications citing this product

  1. Laozhi Xie, .et al. , ACS Nano, 2026, Jun 23;20(24):17442-17462 PMID: 42249854
  2. Salar Ghaffari Gabaran, .et al. , Biochem Pharmacol, 2025, Sep:239:117019 PMID: 40499840
  3. Guohao Wang, .et al. , Nat Commun, 2021, Sep 30;12(1):5733 PMID: 34593794

Added to your cart

View Cart Checkout
Loading...